ANNOUNCEMENT: FDA Clears MiSeqDx Cystic Fibrosis 139-Variant Assay, MiSeqDx Cystic Fibrosis Clinical Sequencing Assay, and MiSeqDx Universal Kit for Use on the MiSeqDx Instrument
The MiSeqDx Cystic Fibrosis 139-Variant Assay, the MiSeqDx Cystic Fibrosis Clinical Sequencing Assay, and the MiSeqDx Universal Kit are the first FDA-cleared next-generation sequencing-based assays and kits for in vitro diagnostic use on the MiSeqDx instrument. These assays and kits enable clinical laboratories to create and deploy next-generation sequencing-based molecular diagnostic tests for cystic fibrosis and a wide range of other applications.
Advancements in genetic analysis are revolutionizing the practice of medicine, improving prenatal and reproductive care, enabling earlier disease detection, and advancing treatment of heritable disease. Novel assays based on next-generation sequencing and microarray technologies are being developed, helping us unlock the power of the genome. When laboratories begin to take advantage of these tools, we will see changes in healthcare in ways never before imagined. Ultimately, paving the way to improving human health.
Cystic fibrosis (CF) is a disease in which early detection and treatment can significantly improve the patient’s quality of life. See more of the data that matters with the MiSeqDx Cystic Fibrosis System, the first and only in vitro diagnostic (IVD) next-generation sequencing (NGS) platform for accurate, comprehensive CF testing. The system includes the MiSeqDx instrument and two assays: the Cystic Fibrosis 139-Variant Assay that detects 139 clinically relevant CFTR variants and the Cystic Fibrosis Clinical Sequencing Assay that accurately captures all variants in the protein coding regions and intron/exon boundaries of CFTR.
Take advantage of powerful NGS technology in building your own IVD assays with the MiSeqDx instrument and MiSeqDx Universal Kit. Together, the MiSeqDx instrument and Universal Kit provide the accuracy and reliability needed to bring NGS into clinical labs. As a result, you can increase the number of diagnostic applications available for your customers.
The American College of Medical Genetics (ACMG) currently recommends the use of microarrays as the first-tier diagnostic test in postnatal cytogenetics for detecting copy number variants (CNVs) associated with intellectual disability, developmental delay, and dysmorphic features. Illumina SNP array technology combines genotype and intensity information to detect chromosomal aberrations, enabling profiling of copy number and copy-neutral events. Additionally, the arrays can identify mosaicism and other factors that can elude standard cytogenetic analysis methods.
Reimbursement coding for clinical laboratories performing molecular diagnostic tests have recently changed. The new Molecular Pathology (MoPath) codes now reflect the purpose of the test instead of the methods used. In addition, new MoPath codes specific for NGS tests have been proposed. In this section, we discuss how these changes affect reimbursement for molecular diagnostic services moving forward.
For In Vitro Diagnostic Use.
Contact an Illumina representative for regional availability.
Understand the 114 new MoPath codes implemented in 2013 and their implications for 2014.